VYNE Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.24 | -$0.24 | -$0.24 |
| Q2 2024 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q3 2024 | 2 | -$0.25 | -$0.21 | -$0.24 |
| Q4 2024 | 1 | -$0.29 | -$0.29 | -$0.29 |
VYNE Therapeutics Inc. Earnings Date And Information
VYNE Therapeutics Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.28546 earnings per share for the quarter, missing analysts' consensus estimates of $-0.23 by $0.05546. The company had revenue of 121,000 for the quarter and had revenue of 424,000 for the year. VYNE Therapeutics Inc. has generated $-3 earnings per share over the last year ($-2.77 diluted earnings per share) and currently has a price-to-earnings ratio of -3.93. VYNE Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
VYNE Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.23 | -$0.29 | -0.06 | $110,000 | $121,000 |
| 08/14/2024 | Q2 2024 | -$0.19 | -$0.22 | -0.03 | $110,000 | $198,000 |
| 05/09/2024 | Q1 2024 | -$0.24 | -$0.15 | 0.09 | $98,000 | |
| 03/01/2024 | Q4 2023 | -$0.20 | $76,000 | |||
| 11/13/2023 | Q3 2023 | -$0.76 | -$2.01 | -1.25 | $150,000 | $114,000 |
| 08/14/2023 | Q2 2023 | -$1.99 | -$3.08 | -1.09 | $50,000 | $135,000 |
| 05/11/2023 | Q1 2023 | -$2.50 | -$1.72 | 0.78 | $99,000 | |
| 03/14/2023 | Q4 2022 | -$2.60 | $6,000 | |||
| 11/14/2022 | Q3 2022 | -$2.94 | $50,000 | $167,000 | ||
| 08/12/2022 | Q2 2022 | -$2.70 | -$2.63 | 0.07 | $100,000 | $126,000 |
| 05/12/2022 | Q1 2022 | -$2.70 | $1.52 | 4.22 | $178,000 | |
| 03/17/2022 | Q4 2021 | -$4.68 | -$3.89 | 0.79 | $2.29 M | |
| 11/10/2021 | Q3 2021 | -$6.12 | -$7.36 | -1.24 | $4.76 M | $4.09 M |
| 08/12/2021 | Q2 2021 | -$6.29 | -$6.98 | -0.69 | $6.35 M | $4.26 M |
| 05/06/2021 | Q1 2021 | -$7.19 | -$7.57 | -0.38 | $4.12 M | |
| 03/04/2021 | Q4 2020 | -$8.99 | -$8.54 | 0.45 | $4.29 M | |
| 11/05/2020 | Q3 2020 | -$12.23 | -$10.61 | 1.62 | $3.31 M | $3.27 M |
| 08/06/2020 | Q2 2020 | -$17.88 | -$86.95 | -69.07 | $1.59 M | $11.69 M |
| 05/11/2020 | Q1 2020 | -$38.88 | -$68.15 | -29.27 | $1.75 M | |
| 03/03/2020 | Q4 2019 | -$59.47 | -$64.36 | -4.89 | $0 |
VYNE Therapeutics Inc. Earnings: Frequently Asked Questions
-
When is VYNE Therapeutics Inc.'s earnings date?
VYNE Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
How can I listen to VYNE Therapeutics Inc.'s earnings conference call?
The conference call for VYNE Therapeutics Inc.'s latest earnings report can be listened to online.
-
How can I read VYNE Therapeutics Inc.'s conference call transcript?
The conference call transcript for VYNE Therapeutics Inc.'s latest earnings report can be read online.
-
How much revenue does VYNE Therapeutics Inc. generate each year?
VYNE Therapeutics Inc. (:VYNE) has a recorded annual revenue of $424,000.
-
How much profit does VYNE Therapeutics Inc. generate each year?
VYNE Therapeutics Inc. (:VYNE) has a recorded net income of $424,000. VYNE Therapeutics Inc. has generated $-2.77 earnings per share over the last four quarters.
-
What is VYNE Therapeutics Inc.'s price-to-earnings ratio?
VYNE Therapeutics Inc. (:VYNE) has a price-to-earnings ratio of -3.93 and price/earnings-to-growth ratio is -0.07.
